Phillip Md Et Al Frost Acquires 100,000 Shares of OPKO Health, Inc. (NASDAQ:OPK) Stock

OPKO Health, Inc. (NASDAQ:OPK) CEO Phillip Md Et Al Frost acquired 100,000 shares of the stock in a transaction that occurred on Friday, November 22nd. The stock was purchased at an average price of $1.59 per share, with a total value of $159,000.00. Following the transaction, the chief executive officer now owns 211,712,405 shares in the company, valued at $336,622,723.95. This represents a 0.05 % increase in their ownership of the stock. The purchase was disclosed in a filing with the SEC, which can be accessed through this hyperlink.

Phillip Md Et Al Frost also recently made the following trade(s):

• On Thursday, November 14th, Phillip Md Et Al Frost acquired 100,000 shares of OPKO Health stock. The stock was purchased at an average price of $1.62 per share, with a total value of $162,000.00.
• On Friday, November 8th, Phillip Md Et Al Frost bought 280,183 shares of OPKO Health stock. The stock was bought at an average cost of $1.50 per share, with a total value of $420,274.50.

OPKO Health Stock Up 1.3 %

Shares of OPK opened at $1.58 on Friday. OPKO Health, Inc. has a 12 month low of $0.85 and a 12 month high of $1.75. The firm’s 50 day moving average is $1.52 and its 200-day moving average is $1.44. The company has a quick ratio of 2.69, a current ratio of 2.97 and a debt-to-equity ratio of 0.30.

Institutional Inflows and Outflows

Several hedge funds have recently made changes to their positions in the business. CIBC Asset Management Inc boosted its position in shares of OPKO Health by 79.1% during the 2nd quarter. CIBC Asset Management Inc now owns 20,322 shares of the biotechnology company’s stock worth $25,000 after acquiring an additional 8,978 shares in the last quarter. Virtu Financial LLC acquired a new stake in shares of OPKO Health during the 1st quarter worth approximately $26,000. FMR LLC boosted its position in shares of OPKO Health by 103.6% during the 3rd quarter. FMR LLC now owns 21,795 shares of the biotechnology company’s stock worth $32,000 after acquiring an additional 11,089 shares in the last quarter. Algert Global LLC acquired a new stake in OPKO Health in the second quarter valued at approximately $44,000. Finally, Orion Portfolio Solutions LLC acquired a new stake in OPKO Health in the third quarter valued at approximately $45,000. 64.63% of the stock is owned by institutional investors.

Analysts Set New Price Targets

OPK has been the subject of a number of research analyst reports. Barrington Research reaffirmed an “outperform” rating and issued a $2.25 target price on shares of OPKO Health in a research note on Friday, November 8th. StockNews.com raised shares of OPKO Health to a “sell” rating in a research note on Saturday, July 27th. Piper Sandler restated an “overweight” rating and set a $3.00 price objective on shares of OPKO Health in a research note on Tuesday, September 17th. Finally, HC Wainwright restated a “buy” rating and set a $3.00 price objective on shares of OPKO Health in a research note on Thursday, September 26th.

OPKO Health Company Profile

OPKO Health, Inc, a healthcare company, engages in the diagnostics and pharmaceuticals businesses in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company's Diagnostics segment operates BioReference Laboratories that offers laboratory testing services for the detection, diagnosis, evaluation, monitoring, and treatment of diseases, including esoteric testing, molecular diagnostics, anatomical pathology, genetics, women's health, and correctional healthcare to physician offices, clinics, hospitals, employers, and governmental units; and 4Kscore prostate cancer test.